Literature DB >> 7559792

Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways.

H W Schnaper1, E S Barnathan, A Mazar, S Maheshwari, S Ellis, S L Cortez, W H Baricos, H K Kleinman.   

Abstract

Endothelial cell differentiation into capillary structures is a complex process that requires the concerted effects of several extracellular matrix proteases, including plasminogen activators. Here, the role of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) was evaluated in an in vitro model of endothelial morphogenesis involving organization of human umbilical vein endothelial cells into tubular structures when they are cultured on the basement membrane preparation, Matrigel. Both uPA and tPA were detected in HUVEC cultures on Matrigel, and inhibitors of plasminogen activators or of serine proteases decreased the extent of the tube network formed by the cells. The decrease resulting from serine protease inhibitors was additive to that from matrix metalloproteinase inhibitors which have previously been shown to decrease tube formation in this model, suggesting that the two classes of proteases modulate tube formation by distinct mechanisms. Plasminogen activator inhibitor (PAI)-1 decreased tube formation by 50% when added up to 4.5 h after the initiation of an 18 h assay and caused 25% inhibition when added 9.5 h after culture initiation, indicating that the effects of plasminogen activators are not limited to an early event in the differentiation process. Steady-state expression of mRNA for uPA increased during the first several hours of culture on Matrigel, further supporting a role for PA activity throughout the process of tube formation. These findings suggested that PAs may affect multiple events during tube-forming activity. A fucosylated peptide comprising the amino-terminal domain of uPA that binds to the uPA receptor (uPAR) but lacking proteolytic activity enhanced tube formation. In contrast, a defucosylated form of the same peptide had no effect. Since fucosylation of this fragment has been shown to be essential in other models of cell stimulation by uPA-uPAR interaction, these data support the hypothesis that uPA enhances endothelial morphogenesis both through proteolytic activity and via uPAR occupancy. Plasminogen activators could facilitate angiogenesis in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7559792     DOI: 10.1002/jcp.1041650114

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  10 in total

1.  Adenovirus-mediated expression of tissue plasminogen activator does not alter endothelial cell proliferation and invasion.

Authors:  D K Zablocki; J J Rade; B R Alevriadou
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Nov-Dec       Impact factor: 2.416

2.  Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation.

Authors:  M S Stack; S Gately; L M Bafetti; J J Enghild; G A Soff
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

3.  Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.

Authors:  Sai Duriseti; David H Goetz; Daniel R Hostetter; Aaron M LeBeau; Ying Wei; Charles S Craik
Journal:  J Biol Chem       Date:  2010-05-25       Impact factor: 5.157

4.  Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells.

Authors:  A H Ree; K Bjørnland; N Brünner; H T Johansen; K B Pedersen; A O Aasen; O Fodstad
Journal:  Clin Exp Metastasis       Date:  1998-04       Impact factor: 5.150

5.  Lipoprotein receptor-related protein 1 regulates collagen 1 expression, proteolysis, and migration in human pleural mesothelial cells.

Authors:  Torry A Tucker; LaTerrica Williams; Kathleen Koenig; Hema Kothari; Andrey A Komissarov; Galina Florova; Andrew P Mazar; Timothy C Allen; Khalil Bdeir; L Vijaya Mohan Rao; Steven Idell
Journal:  Am J Respir Cell Mol Biol       Date:  2012-02       Impact factor: 6.914

6.  Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic.

Authors:  Andrew P Mazar; Richard W Ahn; Thomas V O'Halloran
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

7.  Activated thrombin-activatable fibrinolysis inhibitor attenuates the angiogenic potential of endothelial cells: potential relevance to the breast tumour microenvironment.

Authors:  Zainab A Bazzi; Jennifer Balun; Dora Cavallo-Medved; Lisa A Porter; Michael B Boffa
Journal:  Clin Exp Metastasis       Date:  2017-01-25       Impact factor: 5.150

8.  Live-cell imaging demonstrates extracellular matrix degradation in association with active cathepsin B in caveolae of endothelial cells during tube formation.

Authors:  Dora Cavallo-Medved; Deborah Rudy; Galia Blum; Matthew Bogyo; Dejan Caglic; Bonnie F Sloane
Journal:  Exp Cell Res       Date:  2009-02-03       Impact factor: 3.905

9.  Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity.

Authors:  Marco Rusnati; Antonella Bugatti; Stefania Mitola; Daria Leali; Paolo Bergese; Laura E Depero; Marco Presta
Journal:  Sensors (Basel)       Date:  2009-08-20       Impact factor: 3.576

10.  Newly Identified Peptide, Peptide Lv, Promotes Pathological Angiogenesis.

Authors:  Liheng Shi; Min Zhao; Colette A Abbey; Shu-Huai Tsai; Wankun Xie; Dylan Pham; Samantha Chapman; Kayla J Bayless; Travis W Hein; Robert H Rosa; Michael L Ko; Lih Kuo; Gladys Y-P Ko
Journal:  J Am Heart Assoc       Date:  2019-11-08       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.